Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HN2301 in Generalized Myasthenia Gravis
NCT07556120Phase 1Not yet recruiting
- Sponsor
- Shenzhen MagicRNA Biotechnology
- Start
- Dec 2026
- Primary completion
- May 2027
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HN-2301 in myasthenia gravis (MG), sponsored by Shenzhen MagicRNA Biotechnology. Primary endpoint: Incidence of treatment-emergent adverse events at 3 months. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
HN-2301
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT07556120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07556120.